Leslie Astrid De la Fuente

Leslie Astrid De la Fuente

Auto-generated profile, based on publicly available information

Leslie Astrid De la Fuente

Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Servicio de Oncología, Centro Universitario Contra el Cáncer. Facultad de Medicina, Monterrey, Nuevo León, México

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2026 in World Allergy Organization Journal
Verified
Journal Article
Open access
RGRosalaura Virginia Villarreal Gonzalez
Rosalaura Virginia Villarreal Gonzalez
LFLeslie Astrid De la Fuente
Leslie Astrid De la Fuente
AMAlexia Moreno-Silvestre
Alexia Moreno-Silvestre
MDMaría Guadalupe Durán-Hernández
María Guadalupe Durán-Hernández
DSDiego Armando Sánchez-Alvarado
Diego Armando Sánchez-Alvarado
OGOscar Vidal Gutierrez
Oscar Vidal Gutierrez
Taxanes are widely used in solid tumors but may induce delayed hypersensitivity reactions (DHRs), potentially compromising treatment. The aim was to characterize taxane-related DHRs and evaluate the role of post-medication and rapid drug desensitization (RDD) in treatment continuation. A retrospective, observational study at University Hospital Dr. José Eleuterio González, in Monterrey, Mexico, from January 2020 to May 2025. Patients who developed delayed HSRs following taxane administration were included. After an intravenous challenge test, a post-medication and/or a 3-bag, 12-step rapid drug desensitization (RDD) protocol was applied, adjusted per patient tolerance. Among 4217 patients, 325 (7.7%) developed HSRs; 28 (8.8%) were delayed. Nine cases (32.1%) were attributed to taxanes: 66.6% paclitaxel and 33.4% docetaxel. Most patients were female (88.9%), with a mean age of 52.3 years. The predominant clinical presentation was maculopapular exanthema (77.8%), mainly involving the scalp. Mean time to HSR was 3 days post-infusion, during the second chemotherapy cycle. All patients received 3–7 days of post-medication; 7 of them tolerated the new administration of the drug, while the other 2 underwent a 3-bag, 12-step desensitization. Delayed drug hypersensitivity reactions (DHRs) are a T cell-mediated immune response that occur more than 6 h after exposure, leading to treatment discontinuation or alternative therapies. Management remains poorly defined; however, our findings suggest that pre-medication and RDD may safely support continued chemotherapy. To our knowledge, this is the most extensive reported series of taxane-related DHRs managed with post-medication and RDD in Hispanic population phenotype.

4 August 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RGRosalaura Virginia Villarreal Gonzalez
Rosalaura Virginia Villarreal Gonzalez
ENEduardo Navarro-Bahena
Eduardo Navarro-Bahena
DCDiana Cadenas-García
Diana Cadenas-García
LFLeslie De la Fuente
Leslie De la Fuente
OGOscar Vidal Gutierrez
Oscar Vidal Gutierrez
We present a case of a 41-year-old female diagnosed with Granulosa Cell Tumor (GCT) EC IVB who developed a hypersensitivity reaction (HSR) to carboplatin during the sixth cycle of treatment and subsequently underwent successful intraperitoneal desensitization with cisplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). The patient experienced a severe HSR 30 min after carboplatin infusion, presenting with generalized rash, pruritus, nausea, chest pain, and dyspnea. The infusion was halted, and she was treated with intramuscular epinephrine (0.50 mg), intravenous chloropyramine (20 mg), and 250 mL saline, resolving symptoms. Platinum skin tests were subsequently performed and yielded negative results for carboplatin, cisplatin, and oxaliplatin. Following multidisciplinary consensus, cytoreductive surgery with HIPEC and intraperitoneal desensitization to cisplatin was planned. The patient had a peritoneal carcinomatosis index (PCI) of 17. Cytoreductive surgery included omentectomy, appendectomy, resection of mesenteric implants, diaphragmatic and parietal peritonectomy, in bloc hysterectomy, bilateral salpingo-oophorectomy, and pelvic peritonectomy, achieving a completeness of cytoreduction (CC-0). HIPEC was performed with cisplatin (100 mg/m²) at 42°C for 140 min. A desensitization protocol with intraperitoneal cisplatin (180 mg in 8 incremental steps over 140 min) was successfully completed without adverse reactions. Platinum-based chemotherapeutics are frequently associated with HSR, with increasing incidence upon repeated exposure. Intraperitoneal administration, as in HIPEC, may reduce systemic hypersensitivity risks. While prior cases have demonstrated safe HIPEC administration of cisplatin in patients with oxaliplatin-induced HSR, no documented cases exist of intraperitoneal drug desensitization in this context. Our case suggests that intraperitoneal desensitization with cisplatin may be a viable alternative for patients with systemic HSR to platinum agents. Further research is required to establish safety protocols, cross-reactivity risks, and efficacy outcomes for this approach.

4 August 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RGRosalaura Virginia Villarreal Gonzalez
Rosalaura Virginia Villarreal Gonzalez
LFLeslie Astrid de la Fuente
Leslie Astrid de la Fuente
DGDiana Laura García-Soto
Diana Laura García-Soto
MHMónica Elizabeth Hodoyan-Leal
Mónica Elizabeth Hodoyan-Leal
AVAna Laura Varela-Constantino
Ana Laura Varela-Constantino
OGOscar Vidal Gutierrez
Oscar Vidal Gutierrez
Introduction: Multiple myeloma (MM) is a hematologic cancer characterized by the accumulation of monoclonal plasma cells in the bone marrow. Dexamethasone is included in preferred regimens for primary therapy for both transplant-eligible and transplant-ineligible candidates. To date, type III hypersensitivity reactions to dexamethasone have not been previously reported. Case report: A 61-year-old man diagnosed with multiple myeloma received treatment with bortezomib and dexamethasone, achieving complete remission. In 2017, he experienced his first relapse and was managed with bortezomib, thalidomide, and dexamethasone. In 2019, his regimen was changed to carfilzomib, which was subsequently discontinued due to hematologic toxicity. In 2022, he presented with relapse and an ankle fracture, leading to the suspension of treatment. In 2023, carfilzomib and dexamethasone were restarted at lower doses. During intravenous and oral dexamethasone treatment, the patient developed skin lesions on his lower extremities, and, following evaluation by the Allergy and Immunology team, drug-induced vasculitis was diagnosed. Management and outcome: Given the need to reintroduce dexamethasone due to the lack of alternative therapeutic options, a dexamethasone desensitization protocol was implemented. A 5-step delayed desensitization protocol was successfully performed, with no reactivation of vasculitic lesions. Discussion: Although desensitization is generally contraindicated in type III hypersensitivity reactions, no prior cases of successful desensitization in dexamethasone-induced vasculitis have been reported. This is the first reported case of successful desensitization in a patient with dexamethasone-induced vasculitis. A limitation of this case report is that the mechanisms underlying drug tolerance remain unknown.

28 July 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RGRosalaura Virginia Villarreal Gonzalez
Rosalaura Virginia Villarreal Gonzalez
LFLeslie Astrid De la Fuente
Leslie Astrid De la Fuente
DCDiana Cadenas-García
Diana Cadenas-García
IOItzayana Ortega-Franco
Itzayana Ortega-Franco
MMMarianela Madrazo-Morales
Marianela Madrazo-Morales
OGOscar Vidal Gutierrez
Oscar Vidal Gutierrez
Introduction: Chemotherapy and monoclonal antibodies are increasingly associated with hypersensitivity reactions (HSRs), including anaphylaxis. Desensitization modulates allergic responses to drugs, facilitating temporary tolerance to full therapeutic doses. Methods: Observational, descriptive, ambispective study from August 2020 to August 2024, including cancer patients who came for treatment administration and developed a hypersensitivity reaction, and underwent 3-bag 12-step desensitization in 5.67 h. Demographic variables, atopic and oncological history, hypersensitivity reactions, breakthrough reactions (BTR) during desensitization, and safety of the protocols were reported. Results: 927 desensitization in 219 patients, 20.7% with personal atopy and 84% female. The most common oncological diagnoses were: breast cancer (23.3%), ovarian (22.1%), and cervical (15.9%). The drugs of the most hypersensitivity reactions were Paclitaxel 372 (40.2%), Carboplatin 172 (18.7%), Oxaliplatin 66 (7.1%), Docetaxel 59 (6.4%), Rituximab 40 (4.3%) and Trastuzumab 40 (4.3%). The most frequent hypersensitivity reactions were cutaneous 172 (18.6%), respiratory 173 (18.7%) and cardiovascular 165 (17.8%) with a severity scale of Brown I 12.1%, Brown II 43.3% and Brown III 44.6%. During desensitization 80/927 cases (8.6%) had breakthrough reactions: cutaneous 56 (6%), respiratory 18 (1.9%) and cardiovascular 17 (1.8%), of which the majority were mild reactions. All patients completed their desensitization with no deaths reported. Conclusions: Our study reports that patients undergoing desensitization protocols had a lower percentage of breakthrough reactions compared to the previous hypersensitivity reactions, showing that this procedure is safe and effective to continue first-line oncological treatment.

30 March 2026 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
RGRosalaura Virginia Villarreal Gonzalez
Rosalaura Virginia Villarreal Gonzalez
NGNataly Anais Flores García
Nataly Anais Flores García
LFLeslie Astrid De la Fuente
Leslie Astrid De la Fuente
AOAlira Fraga Olvera
Alira Fraga Olvera
ALAnabel Ávila Lara
Anabel Ávila Lara
YNYahvéh Zecua Nájera
Yahvéh Zecua Nájera
ANTECEDENTES: Las reacciones de hipersensibilidad a medios de contraste yodados representan un problema clínico relevante debido al uso creciente para estudios radiodiagnósticos. Estas reacciones se clasifican en inmunológicas inmediatas, no inmediatas y no inmunológicas, con una prevalencia variable y potenciales consecuencias graves (anafilaxia o reacciones adversas cutáneas graves). La identificación de factores de riesgo, clasificación y mecanismos inmunológicos de los medios de contraste permiten establecer estrategias de prevención y tratamiento. OBJETIVO: Analizar las características químicas de los medios de contraste, mecanismos inmunológicos y métodos diagnósticos disponibles, con la finalidad de establecer estrategias efectivas para su prevención, diagnóstico y tratamiento en poblaciones generales y vulnerables. MÉTODOLOGÍA: Se efectuó una revisión bibliográfica donde se analizaron los diferentes tipos de medios de contraste, según su estructura química, osmolaridad, osmolalidad y viscosidad, destacando su asociación con el riesgo de reacciones de hipersensibilidad. Se describen los mecanismos inmunológicos implicados, incluyendo respuestas mediadas por IgE, células T y el receptor MRGPRX2. Se detallan métodos diagnósticos: estudios in vivo e in vitro, y prueba de exposición controlada, evaluando la sensibilidad, especificidad y utilidad clínica. Se puntualiza la reactividad cruzada entre medios de contraste y la utilidad de agruparlos según sus características químicas para elegir alternativas seguras. Finalmente, se abordan estrategias terapéuticas y preventivas, como la premedicación, la selección del medio de contraste y las consideraciones especiales en poblaciones vulnerables (pacientes pediátricos, mujeres embarazadas y adultos mayores). CONCLUSIONES: La hipersensibilidad a medios de contraste requiere un enfoque diagnóstico y terapéutico multidisciplinario, basado en la adecuada caracterización de la reacción, estudios inmunológicos y selección personalizada del medio de contraste que de administrará. El conocimiento actual permite reducir significativamente la recurrencia de reacciones de hipersensibilidad mediante la sustitución del agente implicado y/o premedicación, optimizando así la seguridad de los procedimientos diagnósticos asociados con medios de contraste. PALABRAS CLAVE: Medios de contraste yodados; Anafilaxia; Prevalencia; Factores de riesgo; Poblaciones vulnerables; Osmolaridad; IgE; Células T; Prueba in vitro; Pacientes pediátricos; Mujeres embarazadas; Hipersensibilidad; Premedicación.